<?xml version="1.0" encoding="UTF-8"?>
<ref id="B193-pharmaceuticals-12-00147">
 <label>193.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Tamura</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Nguyen</surname>
    <given-names>H.T.</given-names>
   </name>
   <name>
    <surname>Sleeman</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Levine</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Mishin</surname>
    <given-names>V.P.</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Guo</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Okomo-Adhiambo</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Stevens</surname>
    <given-names>J.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment</article-title>
  <source>Antimicrob. Agents Chemother.</source>
  <year>2013</year>
  <volume>57</volume>
  <fpage>6141</fpage>
  <lpage>6146</lpage>
  <pub-id pub-id-type="doi">10.1128/AAC.01364-13</pub-id>
  <pub-id pub-id-type="pmid">24080660</pub-id>
 </element-citation>
</ref>
